CinnaGen Reports P-III Clinical Trial Results of Melitide (biosimilar, liraglutide) for the Treatment of Type 2 Diabetes
Shots:
- The new results from a P-III trial evaluating biosimilar liraglutide vs Victoza which showed that biosimilar liraglutide was non-inferior in efficacy to the reference Victoza with a comparable safety profile
- The results demonstrated a similar lowering of HbA1c levels over 26wks. of treatment, as well as comparable effects on body weight, lipid profile, blood pressure, and the incidence of AEs, mean changes in HbA1C (− 1.76% vs − 1.59%)
- Similar findings were obtained with the intention-to-treat analysis with no significant differences’ b/w two study arms & none of the patients developed anti-liraglutide Abs. Liraglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) used for glycemic control in adults with T2D & was approved in the US in Jan 2010
Ref: HCP Live | Image: CinnaGen
Related News:- CinnaGen Reports Study Results of Biosimilar Teriparatide for the Treatment of Osteoporosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
